Read More Pharma Industry News Can Rubraca really replace docetaxel in prostate cancer? FDA just said yes Rubraca becomes first PARP inhibitor approved before chemo in BRCA+ prostate cancer. Find out how TRITON3 data is reshaping treatment strategy. byVenkateshDecember 22, 2025